Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Report

The call conveyed a largely positive commercial and scientific momentum: robust early U.S. launch metrics for IMCIVREE in acquired hypothalamic obesity, 19% sequential product sales growth, encouraging RM-718 early efficacy comparable to existing MC4R agonists, NEJM coverage, and planned international rollouts (Japan and Europe). Key challenges include a one‑time France revenue charge, higher SG&A and continued GAAP losses, some tolerability-related discontinuations in RM-718, and ongoing diagnosis/access constraints that could temper uptake timing. On balance, the growth and pipeline derisking signals materially outweigh the near-term financial and operational headwinds.

The company provided quarterly and full‑year financial and operational guidance and launch metrics: Q2 2026 net product sales were $71.3M (up 19% sequentially from $60.1M in Q1), with $51M (72%) from the U.S., GTN improving to 86%, and patients on reimbursed therapy growing >20% quarter‑over‑quarter; the U.S. HO launch delivered >400 start forms from ~300 prescribers in the first 14 weeks (66 converts from trial patients), ~300 unique prescribers total with 43% adult and 37% pediatric endocrinologists, ~20% of prescribers writing >1 script, 65% of 43 priority accounts activated (delivering ~25% of prescriptions), and payer policies covering ~25% of Medicaid and ~35% of commercial lives by end‑Q2. Q2 operating stats: COGS 12.5% of product revenue, R&D $43.4M (up $1.7M sequentially), SG&A $67.4M (up $3.8M sequentially), total operating expenses ~ $110.9M including $26.1M stock‑based comp, GAAP net loss per share $0.73, cash used in operations ~$9M, and cash/cash equivalents/short‑term investments of ~$331M (expected to fund operations for ≥24 months). Updated 2026 non‑GAAP operating expense guidance is $363M–$397M (R&D $175M–$195M, midpoint reduced by $20M vs. prior expectation; SG&A $188M–$202M unchanged). Clinical and commercial milestones/guidance included RM‑718 Phase II early HO data (11 enrolled, 8 on therapy, 7 at week 16 with mean BMI 40.1 and mean BMI reduction 11.6% at week 16), initiation of bivamelagon Phase III in RH by year‑end, PWS Part D enrollment completion by year‑end (goal 10–15 patients), Japan regulatory/launch target by end‑2026 (estimated 5,000–8,000 patients), and Europe country launches in 2027 (Germany H1 2027), with patent protection for 718 and biva extending past 2040.